Ono Pharmaceutical Co., Ltd. has revealed a strategic partnership agreement with Congruence Therapeutics, a cutting-edge biotechnology company based in Montreal, Canada. This collaboration focuses on developing new small molecule correctors targeting multiple protein pathways in the field of oncology, utilizing Congruence’s signature drug discovery technology, Revenir.
According to the partnership terms, Congruence will employ its Revenir drug discovery platform to create potential small molecule correctors. Ono will gain exclusive rights to globally develop, produce, and market the resulting correctors. Congruence stands to benefit from an initial payment, research funding, development and sales milestone compensations, as well as scaled royalties based on net sales figures.
“This alliance with Congruence is anticipated to advance our efforts in discovering novel small molecule correctors for established oncology targets, drawing upon their expertise in protein dynamics and computational approaches,” expressed Seishi Katsumata, Corporate Officer/Executive Director of Discovery & Research at Ono. “Our aim remains steadfast in providing groundbreaking treatment options for cancer patients at the earliest opportunity.”
Sharath Hegde PhD, Chief Scientific Officer of Congruence, added, “We are excited to collaborate with Ono, recognized as a leading force in drug development, notably in oncology. Our Revenir platform, with its capabilities in protein dynamics, promises to facilitate the swift discovery of innovative therapies for key targets of shared interest.”
Revenir, the proprietary computational platform of Congruence, specializes in assessing the dynamic changes in protein biophysics triggered by mutations. It delivers in-depth insights into protein anomalies and their potential resolution. By analyzing surface properties and a range of biophysical descriptors across various protein structures, Revenir identifies small molecules capable of correcting underlying protein defects.
As a biotechnology firm driven by computational innovation, Congruence is dedicated to establishing a unique array of transformative small molecule correctors strategically devised to restore dysfunctional protein activity.